Wharton Alumni Angels has invited three Life Sciences companies to pitch to it's Members on Wednesday, 27-Sept from 5pm - 6:30pm PT // 8pm - 9:30pm ET.
If you are a WAA member and cannot access Dealum please reach out to [email protected] for assistance.
PROBLEM: Hemorrhage accounts for nearly 2 million deaths/year. For most types of severe, life-threatening hemorrhage, there are no approved therapies that can reach internal, non-compressible bleeding sites. Uncontrolled hemorrhage is also associated with poor long-term outcomes and very high healthcare costs.
SOLUTION: Cayuga's lead drug, CAY001, is a one-time IV injection that accelerates the clotting response. It is based on a polymer is stored in platelets that modulates the kinetics of coagulation. Faster clotting means less blood loss and better survival.
PROBLEM: It's been 116 years since L’Oreal first commercialized permanent color and 73 years after Clairol first introduced a one-step hair bleach formulation. Time has proven permanent color to be highly allergenic and hair bleach to be damaging (and somewhat unpredictable... hello uninvited orange). Edulis was founded on the belief that the way we approach hair color is wrong.
SOLUTION: Melanin-based hair colorant
PROBLEM: Today's bioanalytical methods make biomarker and drug discovery slow and inefficient because end users have to choose between depth and breadth and rely on a hit or miss, iterative confirmation of biological hypothesis. Datasets are blind to the systems biology correlations existing across biological scales leading to inaccurate disease models.
SOLUTION: Our proprietary platform allows us to build unbiased, broad-spectrum mathematical representations of biological samples longitudinally. Our customers use them to perform digital classification, identification of biomarkers and quantitation of small molecules, metabolites, peptides, proteins, organelles in one shot directly in the background matrix.
This is a video event for WAA Members only.
Please register below in advance of this meeting.
Wharton Alumni Angels is not a venture fund, an investment bank, a broker/dealer, investment clearing‐house, or an investment advisor. Wharton Alumni Angels is not registered with the U.S. Securities Exchange Commission or any other state’s or nation’s securities commission. For tax, compliance, reporting, legal or other requirements, it is highly recommended that members seek appropriate professional help. No representation or warranty is made as to the accuracy or completeness of the information provided by Wharton Alumni Angels or companies presenting investment opportunities. Wharton Alumni Angels presumes that any offering conducted by companies is a private placement and does not involve a public solicitation of investment.